oseltamivir

Oseltamivir phosphate (GS 4104) is a neuraminidase (NA) inhibitor with oral activity. Oseltamivir phosphate has antiviral activity and is effective against a wide range of influenza viruses, inhibiting mature influenza viruses from breaking away from host cells.

Oseltamivir (GS 4104) is an orally active and highly potent viral neuraminidase (NA) with antiviral activity, inhibits A H3N2, A H1N2, A H1N1 and influenza B viruses, and can be used in studies of influenza and pneumonia.

Oseltamivir acid (GS4071) is a potent influenza virus neuraminidase inhibitor and the prodrug of GS4071.

Oseltamivir-d3 acid is a deuterated compound of Oseltamivir acid. Oseltamivir acid has a CAS number of 196618-13-0.

Oseltamivir acid methyl ester is a precursor form of oseltamivir acid, which is converted to oseltamivir acid by carboxylesterase 1 (CES1). Oseltamivir acid, in turn, acts as a neuraminidase inhibitor and antiviral agent [1].

Oseltamivir-d3 is a deuterated compound of Oseltamivir. Oseltamivir has a CAS number of 196618-13-0. Oseltamivir (GS 4104) is an orally active and highly potent viral neuraminidase (NA) with antiviral activity, inhibits A H3N2, A H1N2, A H1N1 and influenza B viruses, and can be used in studies of influenza and pneumonia.

Oseltamivir-13C-d3 Acid the 13C and deuterated compound of Oseltamivir Acid. Oseltamivir Acid has a CAS number of 187227-45-8. Oseltamivir acid (GS4071) is a potent influenza virus neuraminidase inhibitor and the prodrug of GS4071.

Oseltamivir EP Impurity C-d3 HCl is a deuterated compound of Oseltamivir EP Impurity C HCl. Oseltamivir EP Impurity C HCl has a CAS number of 1415963-60-8. Oseltamivir carboxylate is an active metabolite of oseltamivir phosphate (Tamiflu).

Oseltamivir-d3 acid(3R,4S,5S) is a deuterated compound of Oseltamivir acid(3R,4S,5S).

Oseltamivir carboxylate is an active metabolite of oseltamivir phosphate (Tamiflu).

Oseltamivir-acetate, an impurity of Oseltamivir, is a recommended neuraminidase inhibitor for both the treatment and prophylaxis of influenza A and B[1][2].

Oseltamivir acid methyl ester hydrochloride is a precursor form of oseltamivir acid. Oseltamivir acid methyl ester is converted to oseltamivir acid converted by carboxylesterase 1 (CES1).

Oseltamivirphosphate-d5 is a deuterated compound of Oseltamivirphosphate. Oseltamivirphosphate has a CAS number of 204255-11-8.

M090 is a potent inhibitor against amantadine-resistant viruses, including the 2009 H1N1 pandemic strains and oseltamivir-resistant viruses.

Influenza virus-IN-8 (compound A4), an inhibitor of the influenza virus (Influenza Virus), functions by inducing aggregation of the viral nucleoprotein (NP) and blocking its accumulation in the nucleus. This compound exhibits broad-spectrum anti-influenza properties, effectively inhibiting the replication and transcription of influenza A virus. Additionally, Influenza virus-IN-8 is effective against Oseltamivir-resistant H1N1 pdm09 strains [1].

The binding affinities of ganoderic acid DM andGanoderic acid ζ (ΔGbind, -16.83 and-10.99 kcal mol-1) are comparable to that of current commercial drug oseltamivir (-23.62 kcal mol-1);Ganoderic acid DM is a potential source of anti-influenza ingredient, with novel binding pattern and advantage over oseltamivir, it has steric hindrance on the 150 cavity of N1 protein, and exerts activities across the H274Y and N294S mutations, is the attractive candidates of novel neuraminidase (NA) inhibitors.Ganoderic acid zeta has cytotoxicity in vitro against Meth-A and LLC cell lines.

CAY10766 is an antiviral compound.1It inhibits entry of influenza virus-like particles pseudotyped with hemagglutinin A (HA) from H5N1 influenza A virus into A549 cells (EC50= 0.24 μM). CAY10766 (1 μM) reduces H1N1 and H5N1 influenza A viral titers in infected MDCK cells. It also exhibits synergy with oseltamivir carboxylate in MDCK cells infected with the influenza A reporter PR8-NS1-Gluc virus.

Spike Binding Peptide 1 (SBP1), representing amino acids 21-43 of angiotensin-converting enzyme 2 (ACE2), has been utilized in a novel approach involving lipid nanoparticles (LNPs) encapsulated with oseltamivir phosphate and conjugated to SBP1. This formulation aims to investigate the possibility of achieving a controlled, long-term in vivo release of oseltamivir phosphate. Furthermore, a 2% concentration of SBP1 immobilized on crosslinked networks composed of hydroxy acrylate and ethylxanthate ethyl acrylate has demonstrated enhanced in vitro efficiency in capturing the spike glycoprotein of severe acute respiratory coronavirus 2 (SARS-CoV-2), also referred to as the surface glycoprotein.

Influenza A virus-IN-4 (compound 23b), a derivative of Oseltamivir, is a highly effective neuraminidase inhibitor that exerts potent inhibitory effects on influenza viruses [1].

Anti-IAV Agent 1-1a is an orally administered compound effective against the Influenza A virus (IAV), demonstrating inhibitory concentration 50 (IC50) values of 0.03 μM and 0.06 μM for the H1N1 strain and the Oseltamivir-resistant H1N1 strain of IAV, respectively.

Anti-Influenza agent 5 (Compound IIB-2), a chalcone-like derivative, serves as an influenza nuclear export inhibitor, effectively inhibiting oseltamivir-resistant strains and hindering viral proliferation by obstructing the export of influenza virus nucleoprotein [1].